Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Exploiting signals of cell-free DNA degradation for clinical research and cancer diagnostics

Award Number: R43CA232935
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 07/03/2018
PERIOD OF PERFORMANCE END DATE: 03/31/2019

Group Awards By:

View Award Description

Exploiting signals of cell-free DNA degradation for clinical research and cancer diagnostics - Summary Claret Bioscience is developing a next-generation sequencing (NGS) library preparation technique that can be deployed as a liquid biopsy DNA assay. Liquid biopsy recovers biomarkers like DNA and other cellular material found circulating in the blood and other bodily fluids, called cell-free DNA (cfDNA). In individuals with tumors, a small portion of the overall cfDNA will derive from the cancerous cells, sharing somatic variants with the tumor itself. Liquid biopsy thus promises a non- invasive means of detecting and genotyping a patient's solid tumor. However, there are few cfDNA- based assays approved today for clinical diagnostic use. They are restricted to relatively few known cancer-driving variants, limiting the scope of cancer screening and the utility of high-throughput sequencers. Claret's solution is an NGS liquid biopsy assay that aims to broadly and agnostically identify DNA of abnormal origin. Our high-throughput assay exploits a novel cfDNA biomarker by recovering and charactering signals of DNA degradation found only at the termini of cfDNA fragments. The major potential outcome of our technology is a liquid biopsy tool that is additive, providing valuable cfDNA sequence data while simultaneously exploiting biologically degraded fragment ends - information lost to all NGS methods to date. The technical challenge of bringing our innovation to the NGS and/or liquid biopsy market hinges on two central challenges. First, the assay must efficiently convert a pool of cfDNA molecules into a sequencing library with high fidelity such that the actual DNA molecular ends are captured. Our first Phase I goal is thus assay optimization. We will measure fidelity, efficiency, reproducibility, sensitivity using a series of experimentally-designed synthetic controls. The second challenge is to discern the biological utility of the characterization of cfDNA termini. We designed our second aim of Phase I to probe for specific signals that may be indicative of disease state and assayable from cfDNA. We focus on matched sets (tissue diseased, tissue normal, blood plasma) of clinical samples from treatment-naïve donors with known cancer types. The proposed Phase I proof-of-concept experiments and assay optimizations will yield a path to a commercially viable product capable of revealing important patterns of DNA degradation from healthy and diseased samples. Project Summary - 1


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2019 ( Subtotal = $0 )
2019	2018	CLARET BIOSCIENCE LLC	567 ASPEN RD	BIRMINGHAM	MI	48009	OAKLAND	USA	Cancer Detection and Diagnosis Research	000	1	5/28/2019	NEW	$0
														Subtotal = $0

Issue Date FY: 2018 ( Subtotal = $298,559 )
2018	2018	CLARET BIOSCIENCE LLC	567 ASPEN RD	BIRMINGHAM	MI	48009	OAKLAND	USA	Cancer Detection and Diagnosis Research	000	1	7/3/2018	NEW	$298,559
														Subtotal = $298,559

Grand Total All Awards = $298,559

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Exploiting signals of cell-free DNA degradation for clinical research and cancer diagnostics

Award Number: R43CA232935

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 07/03/2018

PERIOD OF PERFORMANCE END DATE: 03/31/2019

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer